Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Industry aids Katrina victims

This article was originally published in The Tan Sheet

Executive Summary

The pharmaceutical industry has contributed nearly $25 mil. in medicines, medical supplies and cash to the Hurricane Katrina relief effort as of Sept. 1, "and that number is growing by the hour," according to the Pharmaceutical Research & Manufacturers of America. Abbott, Bayer, GlaxoSmithKline, Johnson & Johnson and Procter & Gamble are among the firms that have contributed, PhRMA notes. The natural products and supplement industry also is initiating relief programs for Katrina's victims. The National Nutritional Foods Association has created the NNFA Retailer Relief Fund to collect donations that will "go directly toward helping NNFA member retailers who sustained damage" due to the storm. Donations may be directed to the relief fund or to the American Red Cross or Salvation Army, NNFA notes...

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS098602

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel